quantic69/iStock via Getty Images
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales
DA Davidson raised the firm’s price target on Old Second Bancorp (OSBC) to $23 from $22 and keeps a Neutral...
Meta CEO Mark Zuckerberg took to his social network Threads two weeks ago to announce Meta Compute, a new “top-level...
Mala Gaonkar’s hedge fund tripled its assets to about $6 billion just three years after it started trading, marking one...
The average 30-year fixed mortgage rate has once again slipped to an important baseline. The current 30-year rate is 6.00%,...
Private lender Kotak Mahindra Bank has reported a 4% YoY (year-on-year) jump in its standalone net profit, reported at Rs...
The primary market will see a relatively quiet week ahead in terms of fresh fundraising, with no mainboard public offerings...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
